Casanova Jean-Laurent, Conley Mary Ellen, Seligman Stephen J, Abel Laurent, Notarangelo Luigi D
St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065 Howard Hughes Medical Institute, New York, NY 10065 Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, 75015 Paris, France Paris Descartes University, Imagine Institute, 75015 Paris, France Pediatric Hematology-Immunology Unit, Necker Hospital for Sick Children, 75015 Paris, France
St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065.
J Exp Med. 2014 Oct 20;211(11):2137-49. doi: 10.1084/jem.20140520. Epub 2014 Oct 13.
Can genetic and clinical findings made in a single patient be considered sufficient to establish a causal relationship between genotype and phenotype? We report that up to 49 of the 232 monogenic etiologies (21%) of human primary immunodeficiencies (PIDs) were initially reported in single patients. The ability to incriminate single-gene inborn errors in immunodeficient patients results from the relative ease in validating the disease-causing role of the genotype by in-depth mechanistic studies demonstrating the structural and functional consequences of the mutations using blood samples. The candidate genotype can be causally connected to a clinical phenotype using cellular (leukocytes) or molecular (plasma) substrates. The recent advent of next generation sequencing (NGS), with whole exome and whole genome sequencing, induced pluripotent stem cell (iPSC) technology, and gene editing technologies-including in particular the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology-offer new and exciting possibilities for the genetic exploration of single patients not only in hematology and immunology but also in other fields. We propose three criteria for deciding if the clinical and experimental data suffice to establish a causal relationship based on only one case. The patient's candidate genotype must not occur in individuals without the clinical phenotype. Experimental studies must indicate that the genetic variant impairs, destroys, or alters the expression or function of the gene product (or two genetic variants for compound heterozygosity). The causal relationship between the candidate genotype and the clinical phenotype must be confirmed via a relevant cellular phenotype, or by default via a relevant animal phenotype. When supported by satisfaction of rigorous criteria, the report of single patient-based discovery of Mendelian disorders should be encouraged, as it can provide the first step in the understanding of a group of human diseases, thereby revealing crucial pathways underlying physiological and pathological processes.
在单个患者身上获得的基因和临床发现能否被认为足以确立基因型与表型之间的因果关系?我们报告称,人类原发性免疫缺陷(PID)的232种单基因病因中,有多达49种(21%)最初是在单个患者中报告的。在免疫缺陷患者中确定单基因先天性错误的能力源于通过深入的机制研究来验证基因型的致病作用相对容易,这些研究利用血样证明了突变的结构和功能后果。候选基因型可以通过细胞(白细胞)或分子(血浆)底物与临床表型建立因果联系。新一代测序(NGS)、全外显子组和全基因组测序、诱导多能干细胞(iPSC)技术以及基因编辑技术(特别是成簇规律间隔短回文重复序列(CRISPR)/Cas9技术)的出现,为不仅在血液学和免疫学领域,而且在其他领域对单个患者进行基因探索提供了新的、令人兴奋的可能性。我们提出了三条标准,用于判断临床和实验数据是否足以仅基于一个病例就确立因果关系。患者的候选基因型不能出现在没有该临床表型的个体中。实验研究必须表明该基因变异损害、破坏或改变了基因产物的表达或功能(或复合杂合性的两个基因变异)。候选基因型与临床表型之间的因果关系必须通过相关的细胞表型得到证实,或者在默认情况下通过相关的动物表型得到证实。当满足严格标准的支持时,应鼓励报告基于单个患者发现的孟德尔疾病,因为它可以为理解一组人类疾病提供第一步,从而揭示生理和病理过程背后的关键途径。